<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020074.anc" start="2765" end="2770" sStart="-1" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="0020075), the initial identification three years ago of resistance mutations against imatinib led to the &lt;b&gt;rapid&lt;/b&gt; development of alternative kinase inhibitors that work even against tumors with the resistance mutation." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0020074.anc" start="2765" end="2770" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="0020075), the initial identification three years ago of resistance mutations against imatinib led to the &lt;b&gt;rapid&lt;/b&gt; development of alternative kinase inhibitors that work even against tumors with the resistance mutation." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020074.anc" start="2431" end="2436" sStart="null" offset="128" sid="r10.find.v.0544" wn="2" wnkey="find%2:39:02::" text="All kinases share some common features, and a resistance mutation very similar to the one identified here has also been found in other kinase genes from tumors with acquired resistance to imatinib, another kinase inhibitor." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020074.anc" start="734" end="742" sStart="null" offset="65" sid="r11.benefit.n.0256" wn="2" wnkey="benefit%1:07:00::" text="Two EGFR inhibitors, gefitinib and erlotinib, showed therapeutic benefits in a subset of patients with non-small cell lung cancer." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020074.anc" start="2198" end="2205" sStart="null" offset="144" sid="r11.absence.n.0195" wn="1" wnkey="absence%1:26:00::" text="It is clear, though, that this is only one mechanism of resistance, because in the three other cases resistance occurred in the absence of the second mutation." />
  </sentences>
</list>